{
  "trial_id": "NCT01004744",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Histologically-confirmed operable ER+ and/or PR+ invasive breast cancer or ductal carcinoma in situ (DCIS)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Postmenopausal status defined as cessation of menses for >1 year or FSH > 20 mIU/mL",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Age \u2265 21 years",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Signed informed consent",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Histologically-confirmed operable ER+ and/or PR+ invasive breast cancer or ductal carcinoma in situ (DCIS), who undergo core needle biopsy followed by surgical excision at least 2 weeks after enrollment",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Treatment with other investigational drugs within 6 months of study entry",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Other serious intercurrent medical illness",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "45-year-old postmenopausal woman with cytologically confirmed breast cancer, HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes.",
  "_meta": {
    "topic_id": "61",
    "trial_id": "NCT01004744",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}